Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis.
Journal
Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
received:
02
02
2022
accepted:
03
08
2022
pubmed:
23
8
2022
medline:
22
3
2023
entrez:
22
8
2022
Statut:
ppublish
Résumé
Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with portal hypertension. JAK2 inhibitors, such as pacritinib, are already in advanced clinical development for other indications and might also be effective in liver fibrosis. Here, we investigated the antifibrotic role of the JAK2 inhibitor pacritinib on activated hepatic stellate cells (HSCs) in vitro and in two animal models of liver fibrosis in vivo . Transcriptome analyses of JAK2 in human livers and other targets of pacritinib have been shown to correlate with profibrotic factors. Although transcription of JAK2 correlated significantly with type I collagen expression and other profibrotic genes, no correlation was observed for interleukin-1 receptor-associated kinase and colony-stimulating factor 1 receptor. Pacritinib decreased gene expression of fibrosis markers in mouse primary and human-derived HSCs in vitro . Moreover, pacritinib decreased the proliferation, contraction, and migration of HSCs. C 57 BL/6J mice received ethanol in drinking water (16%) or Western diet in combination with carbon tetrachloride intoxication for 7 weeks to induce alcoholic or nonalcoholic fatty liver disease. Pacritinib significantly reduced liver fibrosis assessed by gene expression and Sirius red staining, as well as HSC activation assessed by alpha-smooth muscle actin immunostaining in fibrotic mice. Furthermore, pacritinib decreased the gene expression of hepatic steatosis markers in experimental alcoholic liver disease. Additionally, pacritinib protected against liver injury as assessed by aminotransferase levels. This study demonstrates that the JAK2 inhibitor pacritinib may be promising for the treatment of alcoholic and nonalcoholic liver fibrosis and may be therefore relevant for human pathology.
Sections du résumé
BACKGROUND AND AIMS
Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with portal hypertension. JAK2 inhibitors, such as pacritinib, are already in advanced clinical development for other indications and might also be effective in liver fibrosis. Here, we investigated the antifibrotic role of the JAK2 inhibitor pacritinib on activated hepatic stellate cells (HSCs) in vitro and in two animal models of liver fibrosis in vivo .
APPROACH AND RESULTS
Transcriptome analyses of JAK2 in human livers and other targets of pacritinib have been shown to correlate with profibrotic factors. Although transcription of JAK2 correlated significantly with type I collagen expression and other profibrotic genes, no correlation was observed for interleukin-1 receptor-associated kinase and colony-stimulating factor 1 receptor. Pacritinib decreased gene expression of fibrosis markers in mouse primary and human-derived HSCs in vitro . Moreover, pacritinib decreased the proliferation, contraction, and migration of HSCs. C 57 BL/6J mice received ethanol in drinking water (16%) or Western diet in combination with carbon tetrachloride intoxication for 7 weeks to induce alcoholic or nonalcoholic fatty liver disease. Pacritinib significantly reduced liver fibrosis assessed by gene expression and Sirius red staining, as well as HSC activation assessed by alpha-smooth muscle actin immunostaining in fibrotic mice. Furthermore, pacritinib decreased the gene expression of hepatic steatosis markers in experimental alcoholic liver disease. Additionally, pacritinib protected against liver injury as assessed by aminotransferase levels.
CONCLUSIONS
This study demonstrates that the JAK2 inhibitor pacritinib may be promising for the treatment of alcoholic and nonalcoholic liver fibrosis and may be therefore relevant for human pathology.
Identifiants
pubmed: 35993369
pii: 01515467-202304000-00019
doi: 10.1002/hep.32746
pmc: PMC10026969
doi:
Substances chimiques
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
0
Janus Kinase 2
EC 2.7.10.2
Bridged-Ring Compounds
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1228-1240Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
FASEB J. 2019 Aug;33(8):9466-9475
pubmed: 31100032
Expert Rev Hematol. 2014 Jun;7(3):325-32
pubmed: 24746271
F1000Res. 2018 Jan 17;7:82
pubmed: 29399328
Trends Biochem Sci. 1994 Nov;19(11):440-4
pubmed: 7855883
J Biol Chem. 2017 Mar 3;292(9):3789-3799
pubmed: 28100771
Leukemia. 2016 Oct;30(10):2119-2123
pubmed: 27220666
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Sci Rep. 2017 Mar 03;7:42563
pubmed: 28256512
Lancet Haematol. 2017 May;4(5):e225-e236
pubmed: 28336242
Cytokine. 2019 Dec;124:154569
pubmed: 30389231
Blood. 2019 Nov 21;134(21):1832-1846
pubmed: 31511238
Cell Transplant. 2003;12(5):499-507
pubmed: 12953924
Haematologica. 2016 Jun;101(6):660-71
pubmed: 27252511
Hepatology. 2014 Jul;60(1):334-48
pubmed: 24619965
J Biol Chem. 2012 Mar 23;287(13):10277-10288
pubmed: 22275361
Curr Tissue Microenviron Rep. 2021;2(3):41-52
pubmed: 34337431
Lancet Reg Health Eur. 2021 Nov 04;12:100240
pubmed: 34901909
Sci Rep. 2019 Feb 19;9(1):2256
pubmed: 30783172
Gut. 2017 Jan;66(1):145-155
pubmed: 26385087
Blood Adv. 2020 Nov 24;4(22):5825-5835
pubmed: 33232476
Blood. 2012 Feb 23;119(8):1810-20
pubmed: 22186992
J Exp Pharmacol. 2016 Aug 16;8:11-9
pubmed: 27574472
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
J Clin Invest. 2005 Feb;115(2):209-18
pubmed: 15690074
Oncotarget. 2018 Sep 7;9(70):33416-33439
pubmed: 30279971
Hepatology. 2018 Sep;68(3):1125-1139
pubmed: 29537660
Methods Mol Biol. 2017;1627:165-191
pubmed: 28836201
Mol Cancer Ther. 2020 Jan;19(1):231-246
pubmed: 31548294
Sci Rep. 2019 Aug 12;9(1):11598
pubmed: 31406138
Cell Syst. 2018 Nov 28;7(5):556-561.e3
pubmed: 30447998
JAMA Oncol. 2018 May 1;4(5):652-659
pubmed: 29522138
Sci Rep. 2016 Oct 07;6:34719
pubmed: 27713471
Fibrogenesis Tissue Repair. 2013 Oct 01;6(1):19
pubmed: 24274743
J Exp Pharmacol. 2018 May 09;10:9-17
pubmed: 29785143
Am J Physiol Gastrointest Liver Physiol. 2019 Aug 1;317(2):G182-G194
pubmed: 31188634
PLoS One. 2019 Sep 27;14(9):e0222944
pubmed: 31560729
Mol Cell Biol. 2000 May;20(10):3387-95
pubmed: 10779328